Red Flags Detected

• ✓ Material Weakness (removed) — Previously disclosed material weaknesses in inventory valuation and Accelerator Revenue accounting have been remediated; controls now deemed effective.
• ⚠ Asset Impairment (new) — Company recorded a $19.3 million impairment of in-process R&D intangible asset following termination of a diagnostics development agreement with a biopharmaceutical customer.